Valuation : Resverlogix Corp.

Market Cap 2.36Cr 1.71Cr 1.47Cr 1.38Cr 1.26Cr 161.45Cr 2.37Cr 16Cr 6.33Cr 83Cr 6.42Cr 6.28Cr 266.93Cr P/E 2024
-1.38x
P/E 2025 -2.68x
Enterprise Value 11Cr 7.9Cr 6.81Cr 6.41Cr 5.85Cr 747.33Cr 11Cr 76Cr 29Cr 383.39Cr 30Cr 29Cr 1.24TCr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
60.49%
Yield 2024 *
-
Yield 2025 -
1 day-5.00%
6 months-29.63%
Current year-5.00%
1 week 0.09
Extreme 0.09
0.1
1 month 0.09
Extreme 0.09
0.11
Current year 0.08
Extreme 0.085
0.14
1 year 0.08
Extreme 0.085
0.15
3 years 0.04
Extreme 0.035
0.3
5 years 0.04
Extreme 0.035
0.82
10 years 0.04
Extreme 0.035
4.94
Manager TitleAgeSince
Chief Executive Officer - 25/04/2003
Director of Finance/CFO 78 29/10/2009
Chief Tech/Sci/R&D Officer - 15/08/2022
Director TitleAgeSince
Chairman - 04/04/2016
Director/Board Member 56 15/10/2009
Director/Board Member 66 29/09/2010
Date Insider Type Main position Quantity % Market Cap. Importance
06/07/26 Option

Chief Financial Officer

3,50,000 0.1018%
06/07/26 Option

Chief Financial Officer

-3,50,000 0.1018%
06/07/26 Option

Chief Executive Officer

5,00,000 0.1454%
Change 5-day change 1-year change 3-year change Capi.($)
-5.00%0.00%-5.00%+18.75% 2.36Cr
-1.79%-2.27%+43.23%+88.96% 6.8TCr
-2.06%-0.18%+39.67%+86.44% 6.49TCr
-0.31%+6.54%-12.96%+378.92% 2.76TCr
+0.86%+1.65%-7.74%-14.95% 2.61TCr
-3.00%-2.90%+33.13%+12.54% 2.57TCr
-1.46%+0.42%+23.61%-18.61% 2.01TCr
-2.96%-15.21%+216.20%+368.10% 1.72TCr
-1.49%-4.88%-6.60%+531.89% 1.49TCr
-0.20%+8.37%+55.78%+164.98% 1.46TCr
Average -1.74%+0.23%+37.93%+161.70% 2.79TCr
Weighted average by Cap. -1.52%+0.18%+38.37%+137.34%

Financials

2024 2025
Net sales - -
Net income -76.35L -55.15L -47.52L -44.7L -40.84L -52Cr -76.6L -5.28Cr -2.04Cr -27Cr -2.07Cr -2.03Cr -86Cr -77.67L -56.1L -48.35L -45.48L -41.55L -53Cr -77.92L -5.37Cr -2.08Cr -27Cr -2.11Cr -2.06Cr -88Cr
Net Debt 8.19Cr 5.91Cr 5.1Cr 4.79Cr 4.38Cr 559.12Cr 8.21Cr 57Cr 22Cr 286.83Cr 22Cr 22Cr 924.41Cr 8.58Cr 6.2Cr 5.34Cr 5.02Cr 4.59Cr 585.89Cr 8.61Cr 59Cr 23Cr 300.56Cr 23Cr 23Cr 968.66Cr
Logo Resverlogix Corp.
Resverlogix Corp. is a Canada-based late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. The Company focuses on the development of a new class of therapeutics: bromodomain and extraterminal domain (BET) protein inhibitors. BET proteins play a central role in epigenetics and enable the transcription of disease-causing genes. Its small molecule BET inhibitors are designed to exploit this central epigenetic role to regulate gene expression and tackle the root causes of chronic diseases. The Company's clinical program focuses on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post-COVID-19 conditions. It partners with EVERSANA to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Employees
-
Date Price Change Volume
04/26/04 CA$0.0950 -5.00% 600
03/26/03 CA$0.1000 +5.26% 1,600
02/26/02 CA$0.0950 0.00% 64,000
01/26/01 CA$0.0950 0.00% 11,979
31/26/31 CA$0.0950 0.00% 31,313
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!